Day: May 13, 2022

-General Alignment with FDA on Key Aspects of Design of Proposed Additional Clinical Trial- -Cash Runway into 2024- DUBLIN, Ireland and CHICAGO, May 13, 2022 (GLOBE NEWSWIRE) — Iterum Therapeutics plc (Nasdaq: ITRM) (“Iterum”), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today reported financial results for the first quarter ended March 31, 2022. “As reported earlier this week, we have reached general alignment with the U.S. Food and Drug Administration (“FDA”) on key aspects of the proposed design of an additional clinical trial comparing oral sulopenem to Augmentin® (amoxicillin/clavulanate) for the treatment of uncomplicated urinary tract infection (“uUTI”) in adult women...

TORONTO, Ontario and CAMBRIDGE, Massachusetts, May 13, 2022 (GLOBE NEWSWIRE) — ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF) (“ProMIS” or the “Company”), a biotechnology company focused on the discovery and development of antibody therapeutics targeting misfolded proteins such as toxic oligomers, implicated in the development of neurodegenerative diseases, today announced its operational and financial results for the three months ended March 31, 2021. “In Q1 of 2022 we have continued the significant progress of late 2021, advancing and expanding our portfolio of differentiated therapeutic product candidates in diseases such as Alzheimer’s disease (AD), ALS, and schizophrenia,” said Gene Williams, ProMIS’ Chairman and CEO. “Our lead program PMN310 for Alzheimer’s continues rapid progress to an IND filing and clinical trials....

Total revenue was €23.9 mm in Q1 2022 (20% above Q1 2021), while net gaming revenue was €25.5 mm in the period, 24% above Q1 20211.Mexico revenue was €8.9 mm in Q1 2022 (55% above Q1 2021), while Mexico net gaming revenue was €10.0 mm in the period, 56% above Q1 2021.Spain revenue (and net gaming revenue) reached €13.2 mm in Q1 2022, above Q1 2021 (pre-regulation) levels.Net loss was €10.1 mm in Q1 2022 versus a €6.1 mm loss in Q1 2021.Strong available cash position of over $100 mm (€91 mm) as of March 31, 2022.Madrid, Spain and Tel Aviv, Israel, May 13, 2022 (GLOBE NEWSWIRE) – Codere Online (Nasdaq: CDRO / CDROW), a leading online gaming operator in Latin America, has released its financial results for the first quarter ended March 31, 2022. Below are the main financial and operating metrics of the period.  Quarter ended...

FDA approval for EPSOLAY® (benzoyl peroxide, cream, 5%) represents Sol-Gel’s second approved product within less than a year; EPSOLAY is patent protected until 2040Partner Galderma to launch two products in the U.S. this quarter: TWYNEO launched in the U.S. market in April for the topical treatment of acne vulgaris in patients nine years of age and older and EPSOLAY to launch in the second quarter for the treatment of inflammatory lesions of rosacea in adultsSol-Gel’s cash runway expected to extend through the end of 2023NESS ZIONA, Israel, May 13, 2022 (GLOBE NEWSWIRE) — Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company focused on identifying, developing, commercializing or partnering branded and generic topical drug products for the treatment of skin diseases, announced today financial results for the first...

— Human Acellular Vessels™ (HAVs™) shipped to six hospitals in Ukraine for treatment of civilian and military vascular trauma injuries — — Strengthened leadership team with appointment of Shamik Parikh M.D., as Chief Medical Officer —  — Multiple scientific meeting presentations and publications highlighting clinical and preclinical HAV data — — Conference call and live webcast at 8:00 a.m. ET today — DURHAM, N.C., May 13, 2022 (GLOBE NEWSWIRE) — Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissues, complex tissue systems, and organs at commercial scale, today announced financial results for the first quarter ended March 31, 2022, and highlighted recent corporate accomplishments. “We are pleased...

Atlanta, GA, May 13, 2022 (GLOBE NEWSWIRE) — Trust Stamp (Nasdaq: IDAI, Euronext Growth: AIID ID), the Privacy-First Identity CompanyTM providing AI-powered trust and identity services used globally across multiple sectors, provides a business update and commentary on reported financial results for the three months ended March 31, 2022 (“Q1 2022”). First Quarter 2022 Financial Highlights:Net Revenue was $2.82M in Q1 2022 compared to $0.53M in Q1 2021, a 430.0% increase year-over-year Gross Profit was $2.13M in Q1 2022 compared to $0.27M in Q1 2021, a 673.8% increase year-over-year Gross Profit Margin for Q1 2022 was 75.4% compared to 51.6% for Q1 2021 Operating Loss decreased to $1.64M in Q1 2022 compared to $1.94M in Q1 2021 Net Profit Margin increased to -60.0% in Q1 2022 from -381.7% in Q1 2021 Net Loss was $1.69M in Q1 2022...

ORLANDO, Fla., May 13, 2022 (GLOBE NEWSWIRE) — Gencor Industries, Inc. (Nasdaq: GENC) announced today net revenues of $30.7 million for the quarter ended March 31, 2022 compared to $21.4 million for the quarter ended March 31, 2021. Gross margins for the quarter ended March 31, 2022 were 20.2% compared with 28.8% for the quarter ended March 31, 2021. During the quarter ended March 31, 2022, the Company continued to experience higher manufacturing costs associated with wages, steel and OEM parts pricing. Product engineering and development expenses decreased $0.2 million to $0.9 million for the quarter ended March 31, 2022, as compared to $1.1 million for the quarter ended March 31, 2021, primarily related to reduced headcount. Selling, general and administrative (“SG&A”) expenses decreased by $0.5 million to $3.4 million for...

CHERRY HILL, N.J., May 13, 2022 (GLOBE NEWSWIRE) — The Real Good Food Company, Inc. (Nasdaq: RGF) (“Real Good Foods” or the “Company”), an innovative, high-growth, branded, health- and wellness-focused frozen food company, today reported financial results for its first quarter ended March 31, 2022. “We had strong momentum entering 2022 and I am pleased to report our first quarter results exceeded our expectations and we are raising our guidance for the full year,” said Bryan Freeman, Executive Chairman. “We achieved broad-based growth across our sales channels as well as significant sequential gross margin improvement in the first quarter. Due to productivity initiatives, we now expect to be Adjusted EBITDA positive in the fourth quarter of 2022. We believe we are still in the early stages of a robust long-term growth journey and...

Conference Call to Be Held Today at 10:00 am ET QUINCY, Mass., May 13, 2022 (GLOBE NEWSWIRE) — Stran & Company, Inc. (“Stran” or the “Company”) (NASDAQ: STRN) (NASDAQ: STRNW), a leading outsourced marketing solutions provider that leverages its promotional products and loyalty incentive expertise, today provided a business update and reported financial results for the three months ended March 31, 2022. Andy Shape, President and CEO of Stran, commented, “We continue to successfully execute on our business strategy, as demonstrated by a 62.5% increase in revenue to $12.3 million for the first quarter of 2022, compared to the same period last year. Furthermore, we completed the highly synergistic and accretive acquisition of G.A.P. Promotions in January 2022. G.A.P. expands our reach within the beverage...

NOT FOR DISTRIBUTION TO U.S. NEWSWIRES OR OTHER DISSEMINATION IN THE UNITED STATES TORONTO, May 13, 2022 (GLOBE NEWSWIRE) — Ceres Acquisition Corp. (NEO: CERE.U, CERE.WT; OTCQX: CERAF) (“Ceres” or the “Corporation”) is reporting its financial results as at March 31, 2022 and March 31, 2021, and for the three month periods then ended. The Corporation’s unaudited financial statements, along with the accompanying management’s discussion and analysis, have been filed on the System for Electronic Document Analysis and Retrieval (SEDAR) and may be viewed by interested parties under the Corporation’s profile at www.sedar.com. The Corporation is confident in its abilities to identify, evaluate and execute an attractive qualifying transaction by continuing to leverage its network to source a wide spectrum of meaningful investment opportunities. About...